dc.contributor.author | M. El-Deeb, Ibrahim | |
dc.contributor.author | M. Bayoumi, Said | |
dc.contributor.author | A. El-Sherbeny, Magda | |
dc.contributor.author | A.-M. Abdel-Aziz, Alaa | |
dc.date.accessioned | 2017-05-03T15:59:05Z | |
dc.date.available | 2017-05-03T15:59:05Z | |
dc.date.issued | 2010 | |
dc.date.modified | 2011-07-20T07:06:41Z | |
dc.identifier.issn | 02235234 | |
dc.identifier.doi | 10.1016/j.ejmech.2010.02.038 | |
dc.identifier.uri | http://hdl.handle.net/10072/37838 | |
dc.description.abstract | Novel derivatives of 5-(substituted)benzylidene-3-(4-substituted)phenylsulfonylimidazolidine-2,4-diones (3a-r), 1-(4-substituted)phenylsulfonyl-3-(4-substituted)phenylpyrimidine-2,4,6-(1H,3H,5H)-triones (6a-l), and 3-(4-substituted)phenyl-1-(4-substituted)phenylsulfonylquinazoline-2,4(1H,3H)- diones (8a-l) have been synthesized and tested for their antitumor activity against 60 tumor cell lines taken from 9 different organs. The tested compounds have showed good inhibitory effect at the ovarian cancer (IGROV1) cell line. A significant inhibition for (RXF393) renal cancer cells was observed with series 3 compounds, while in the other two series 6 and 8, there was a significant inhibition of ovarian cancer cells (OVCAR-8) and melanoma cells (SK-MEL-2). Interestingly; beside the strong inhibition of compound 3q to IGROV1 and RXF393 cells, a great inhibition (199.62%) for (M14) Melanoma cells was observed at the tested concentration (10 卩. ADME-T and pharmacophore prediction methodology were used to study the antitumor activity of the most active compounds and to identify the structural features required for antitumor activity. | |
dc.description.peerreviewed | Yes | |
dc.description.publicationstatus | Yes | |
dc.format.extent | 811332 bytes | |
dc.format.mimetype | application/pdf | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.publisher.place | France | |
dc.relation.ispartofstudentpublication | N | |
dc.relation.ispartofpagefrom | 2516 | |
dc.relation.ispartofpageto | 2530 | |
dc.relation.ispartofissue | 6 | |
dc.relation.ispartofjournal | European Journal of Medicinal Chemistry | |
dc.relation.ispartofvolume | 45 | |
dc.rights.retention | Y | |
dc.subject.fieldofresearch | Medicinal and biomolecular chemistry | |
dc.subject.fieldofresearch | Biologically active molecules | |
dc.subject.fieldofresearch | Organic chemistry | |
dc.subject.fieldofresearch | Pharmacology and pharmaceutical sciences | |
dc.subject.fieldofresearchcode | 3404 | |
dc.subject.fieldofresearchcode | 340401 | |
dc.subject.fieldofresearchcode | 3405 | |
dc.subject.fieldofresearchcode | 3214 | |
dc.title | Synthesis and Antitumor Evaluation of Novel Cyclic Arylsulfonylureas: ADME-T and Pharmacophore Prediction | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dc.type.code | C - Journal Articles | |
gro.rights.copyright | © 2010 Elsevier Inc. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version. | |
gro.date.issued | 2010 | |
gro.hasfulltext | Full Text | |
gro.griffith.author | El-Deeb, Ibrahim Mustafa | |